Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reiterated by FinnCap in a note issued to investors on Tuesday. They presently have a GBX 70 ($0.92) target price on the stock. FinnCap’s price objective would suggest a potential upside of 117.05% from the company’s previous close.

Separately, Numis Securities Ltd restated a “buy” rating and issued a GBX 80 ($1.05) price target on shares of Abzena PLC in a research report on Thursday, September 14th.

Shares of Abzena PLC (LON:ABZA) remained flat at $GBX 32.25 ($0.42) during trading hours on Tuesday. Abzena PLC has a 52 week low of GBX 27.73 ($0.36) and a 52 week high of GBX 66 ($0.87).

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/23/finncap-reaffirms-buy-rating-for-abzena-plc-abza.html.

Abzena PLC Company Profile

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related companies with MarketBeat.com's FREE daily email newsletter.